MEDICAL SPECIALTIES HEALTH CONDITIONS PRODUCTS REIMBURSEMENT Home About Us News Careers Investor Relations Europe Boston Scientific announces CE mark for MRI labeling of EMBLEM™ S-ICD Systems   LOTUS Edge™ VALVE SYSTEM Advancing Control Simplified Delivery & Deployment Complete Repositionability Unmatched Freedom from PVL1-7 Learn More         For Physicians Discover a medical specialty and related resources. For Patients Find information on conditions and learn about our treatment options. Find Products Explore product details and how we innovate. TOOLS Find out in seconds if your Boston Scientific pacemaker or defibrillator system is safe for MRI CAREERS Become a part of Boston Scientific ABOUT US Learn more about Boston Scientific Europe INNOVATION PORTAL Do you have an innovative idea? Submit your idea * Holmes D, Doshi S, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient Level Meta-analysis of WATCHMAN Trials; JACC, In print, 2015. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. In countries where CE is the regulation in force, the WATCHMANTM LAA Closure Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy. In the USA the WATCHMANTM LAA Closure Technology is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who: • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy; • Are deemed by their physicians to be suitable for warfarin; and • Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin. The WATCHMANTM Access System is intended to provide vascular and transseptal access for all WATCHMANTM Left Atrial Appendage Closure Devices with Delivery Systems. All cited trademarks are the property of their respective owners. Disclaimer: Please be informed that in some EU countries (Bulgaria, Cyprus, Estonia, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Belgium , Netherlands, Slovenia and Spain) medical device advertisement to general public is not permitted. Therefore, if you are accessing this website from one of those countries and you are not a healthcare professional, you need to exit this site immediately, since you would be viewing information that may not be legally allowed under the laws of your country of residence. Should you disregard this warning notice, Boston Scientific declines any liability as to your access to such information. Eluvia Drug-Eluting Stent System CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. This material is not for use or distribution in France. Eluvia is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are property of their respective owners. 2016 Copyright © Boston Scientific Corporation. All rights reserved. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Locations Site Map Privacy Policy Terms of Use Copyright Notice ©2016 Boston Scientific Corporation or its affiliates. All rights reserved. CORP-275222-AA OCT2014, CRM-337901-AA AUG 2015, ENDO-349501-AA OCT 2015, URO/WH-360310–AB MAR2016, PI-373702-AA FEB2016 Eluvia, SH- 414904-AA JUL2016